DAW: Duplicate-AWare Federated Query Processing over the Web of Data

Abstract. Over the last years the Web of Data has developed into a large compendium of interlinked data sets from multiple domains. Due to the decentralised architecture of this compendium, several of these datasets contain duplicated data. Yet, so far, only little attention has been paid to the effect of duplicated data on federated querying. This work presents DAW, a novel duplicate-aware approach to feder-ated querying over the Web of Data. DAW is based on a combination of min-wise independent permutations and compact data summaries. It can be directly combined with existing federated query engines in or-der to achieve the same query recall values while querying fewer data sources. We extend three well-known federated query processing engines – DARQ, SPLENDID, and FedX – with DAW and compare our exten-sions with the original approaches. The comparison shows that DAW can greatly reduce the number of queries sent to the endpoints, while keeping high query recall values. Therefore, it can significantly improve the performance of federated query processing engines. Moreover, DAW provides a source selection mechanism that maximises the query recall, when the query processing is limited to a subset of the sources

Anticancer activity of a new pharmaceutical composition of diindolylmethane by inhibiting the cell viability in vitro

We have studied antitumor effects of a new pharmaceutical composition with improved bioavailability containing 3,3’-diindolylmethane (DIM) by in vitro modelling. Cytotoxicity of the test substance was determined by MTT assay. Pharmaceutical composition based on DIM inhibits the growth of tumor cell lines of endometrial cancer CRL-1622 (IC50 = 41,9 µM) and HTB-113 (IC50 = 52,2 µM). Results of the study allow to recommend the further investigation of antitumor activity in vivo

Conservative therapy with CIN I-II vaginal suppositories Cervicon-Dim (intermediate results of a clinical study)

CIN is most common in women of reproductive age. The current treatment standards for CIN I and/or CIN II are invasive and aggressive, which sometimes leads to a disruption of reproductive function. At the same time, long-term follow-up and non-intervention can result in further progression of the process. Therefore the search for conservative treatment of CIN I-II remains a challenging task. We conducted a multicenter, randomized, placebo-controlled, double-blind, parallel group study which showed that administration of Cervicon-DIM vaginal suppositories for 90 days at a dose of 200 mg/day or 100 mg/day is associated with improved histological condition of CIN I-II and even leads to cure